Search

O presente trabalho busca analisar as principais transformações e permanências relacionadas ao fenômeno do turismo de segunda residência frente ao contexto da pandemia do Sars-Cov-2 no Brasil, entendida aqui como elemento acelerador de processos que já vinham sendo experienciados pelo fenômeno antes da crise sanitária. Parte-se do entendimento de que as chamadas residências secundárias, sua espacialização e as dinâmicas a elas atreladas se expressam por meio de uma imbricada relação de fatores e contradições socioespaciais. Nesse sentido, em que pese a ocorrência de transformações quanto ao uso das residências secundárias, verifica-se que essa prática continua a convergir para uma, cada vez maior, possibilidade de ganhos financeiros e para uma maior desigualdade e segregação socioespacial. Os resultados demonstram que a pandemia tem tido papel relevante na aceleração desses processos. Tomam-se, como casos exemplares da investigação, dois importantes balneários turísticos litorâneos, onde há forte incidência de residências secundárias, Bertioga/SP e Armação dos Búzios/RJ, que, pela proximidade às duas principais metrópoles nacionais, São Paulo e Rio de Janeiro, respectivamente, mantêm com estas fortes relações concernentes ao turismo. As análises, fundamentalmente qualitativas, são complementadas por dados quantitativos relacionados ao fenômeno em estudo, subsidiando as inferências e as interpretações dos achados. Le présent travail vise à analyser les principales transformations et permanences liées au phénomène du tourisme de résidence secondaire dans le contexte de la pandémie de Sars-Cov-2 au Brésil, entendu ici comme un élément accélérateur de processus déjà vécus par le phénomène avant la crise sanitaire. Nous partons du constat que les résidences dites secondaires, leur spatialisation et les dynamiques qui leur sont liées s'expriment à travers une relation imbriquée de facteurs socio-spatiaux et de contradictions. En ce sens, malgré l'apparition de transformations concernant l'usage des résidences secondaires, il apparaît que cette pratique continue de converger vers une possibilité de plus en plus grande de gains financiers et vers une plus grande inégalité et ségrégation socio-spatiale. Les résultats ont montré que la pandémie a joué un rôle important dans l'accélération de ces processus. Deux importantes stations touristiques côtières, où il y a une forte incidence de résidences secondaires, Bertioga/SP et Armação dos Búzios/RJ, qui, en raison de leur proximité avec les deux principales métropoles nationales, São Paulo et Rio de Janeiro, respectivement, maintiennent avec ces relations fortes autour du tourisme. Les analyses qualitatives sont complétées par des données quantitatives liées au phénomène à l'étude, soutenant les inférences et les interprétations des résultats. This work analyzes the main transformations and permanencies related to the phenomenon of second-home tourism in the Sars-Cov-2 pandemic context in Brazil, understood here as an accelerating element of processes that were already being experienced by the phenomenon before the sanitary crisis. It starts from the understanding that the so-called secondary homes, their spatialization and the dynamics linked to them are expressed through an imbricated relationship of socio-spatial factors and contradictions. In this sense, despite the occurrence of transformations regarding the use of secondary homes, it appears that this practice continues to converge to an increasingly greater possibility of financial gains and to greater inequality and socio-spatial segregation. The findings have shown that the pandemic has played a relevant role in accelerating these processes. Two important coastal tourist resorts, where there is a strong incidence of secondary homes, Bertioga/SP and Armação dos Búzios/RJ, which, due to their proximity to the two main national metropolises, São Paulo and Rio de Janeiro, respectively, maintain with these strong relations concerning tourism. The qualitative analyses are complemented by quantitative data related to the phenomenon under study, supporting the inferences and interpretations of the findings.

Deliverable D4.3 reinforces and generalizes the results of the research activities conducted and summarised in deliverable D4.1 on ``Initial results on adaptive directional LOS and NLOS reliable connectivity''. In this direction, the present deliverable focuses on optimization and machine learning techniques tailored to the physical and medium access layers requirements of fully reconfigurable environments. Overall, the results reported in this deliverable allowed us to assess the major performance gains that the deployment of RISs in high frequency bands bring about for application to future wireless communication systems.

Rationale: Follicular non-Hodgkin lymphoma (fNHL) is a neoplasm characterized by an indolent course and chemosensitivity, but also by disease recurrence. Bendamustine is often used as frontline treatment or second line. Heading diagnosis: fNHL. Patient concerns: A 63-year-old Caucasian male with diagnosis of fNHL lymphoma underwent to cyclophosphamide, doxorubicin, vincristine, and prednisone associated with rituximab chemoimmunotherapy, during which interim reevaluation showed progressive disease and severe toxicity. Interventions: Early switch to rituximab-bendamustine. Outcomes: This regimen was well tolerated, patient compliance was optimal, there were no delays in administration and no infectious episodes. An interim reevaluation after 3 courses revealed that the patient was fit, the blood cell count was normal, and lymphadenopathies and nocturnal sweating had completely regressed. Of note, the PET/CT scan did not show fluorodeoxyglucose pathological uptake, clearly confirming disease regression. Lessons: Early switching to a bendamustine-rituximab-based scheme, even during conventional chemotherapy, decreases toxicity and reduces the risk of treatment interruption or delay, with favorable effects on overall response and prognosis.

This deliverable brings the final results on directional links' analysis and algorithm design. The results, models, and analysis herein append the results given in the previous deliverable (D2.1) of Task 2.1 of the ARIADNE project. This deliverable reports the models and analysis for practical hardware imperfections, reconfigurable intelligent surface (RIS) gain properties, RIS beamforming algorithms, and performance analysis of RIS-aided links in this deliverable.

BACKGROUND We evaluated the role of [18F]FDG PET/CT in tumor response assessment and prognosis of primary extranodal lymphoma (PEL) patients. METHODS We examined retrospectively, 56 PEL patients: 31 with aggressive diffuse large B cell lymphoma (DLBCL) and 25 with indolent lymphoma (20 mucosa-associated lymphoid tissue lymphoma and five follicular lymphoma). All patients had undergone [18F]FDG PET/CT at diagnosis (PET-I) and 50 of them also after therapy (PET-II). Moreover, 52 patients were subjected to a mean follow-up period of 76 months. RESULTS PET-I was positive in 50 (89%) patients (mean SUVmax 10.3±6.7). In the assessment of tumor response, according to Lugano classification, 45 patients showed complete metabolic response (CMR), four patients had partial metabolic response (PMR) and one had progressive metabolic disease (PMD). Based on 66% ΔSUVmax cut-off, among CMR patients, 41 showed a ΔSUVmax>66% whereas among non-responders, four patients showed a ΔSUVmax

Background In this prospective study, the impact of granulocyte colony-stimulating factors (G-2 CSF) administered during induction treatment with bendamustine plus rituximab for indolent non- Hodgkin Llymphoma (NHL) was evaluated by comparing patients who received secondary prophylaxis with filgrastim (control group) versus. patients who received pegfilgrastim as primary prophylaxis (peg-group). The primary endpoint was the incidence rate of febrile neutropenia (FN)- related chemotherapy disruptions (regarding dose-dense and/or dose-intensity of schedule). The Ssecondary endpoint included days of hospitalization due to FN, and G-CSF-related side effects (grade ≥3 WHO toxicity criteria) in each group. Methods One hundred twenty-two: 122 consecutive patients, with untreated indolent NHL, were referred to our outpatient unit for remission induction immuno-chemotherapy with bendamustine-rituximab. During the first period, 61 patients received secondary prophylaxis with filgrastim, given “on demand” if ANC was

The association of hepatitis C virus (HCV) with non-Hodgkin's lymphoma (NHL) has been demonstrated throughout the world. The new interferon-free direct antiviral agents (DAAs) showed high efficacy and safety, and preliminary data seem to confirm their activity on low-grade NHL. The question arises as whether or not—and how—to treat the HCV-positive patients suffering from diffuse large B-cell lymphomas (DLBCLs). The aim of this observational study was to evaluate whether DAA antiviral treatment of DLBCL/HCV-infected patients in concomitance with chemotherapy is a safe and effective option. Twenty (13 males and 7 females) HCV genotype 1b-positive subjects, undergoing chemotherapy for DLBCL, were enrolled between June 2015 and December 2015. After informed consent, all patients underwent antiviral therapy (AVT) with sofosbuvir/ledipasvir and chemotherapy (14 rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone and 6 cyclophosphamide, doxorubicin, vincristine, and prednisone) for DLBCL. Complete hematological (Revised European-American Lymphoma classification, Ann Arbor, and International Prognostic Index [IPI] scores) and hepatological (viral markers, liver stiffness, and biochemical parameters) evaluations were made. A historical retrospective cohort of 101 DLBCL/HCV-positive patients not undergoing AVT was enrolled for comparison. DAA-treated and untreated patients were similar for sex distribution, IPI score, and NHL stage, and differed for age (older in treated), chemotherapy and use of AVT. Overall survival (OS) and disease-free survival (DFS) were evaluated among a 52-week of follow-up. No statistical difference was found in OS after 52 weeks (P = 0.122), whereas a statistically significant higher DFS was achieved in treated patients (P = 0.036). At the multivariate analysis, only IPI score and AVT were independently correlated with a better DFS. No differences in adverse events were reported. Conclusion: DAA treatment in concomitance with chemotherapy was shown to be safe and effective in influencing remission of aggressive lymphomas in HCV patients. (Hepatology 2018;67:48-55).

Introduction Peri-implant breast seroma is a late clinical presentation of reconstructive surgery or augmentation mammoplasty with breast implants. Pre-operative cytological evaluation of the peri-implant breast seroma is a common clinical approach, showing mainly an inflammatory reaction or more rarely a breast implant-associated anaplastic large cell lymphoma. Herein, we reported the role of cytology in the evaluation of peri-implant breast seroma and its critical pre-operative implications. Methods Eight cases of peri-implant breast seroma from files at Luigi Vanvitelli University were identified between January and December 2017. In all cases, seroma was aspirated; cytospins were performed and stained by Papanicolaou stain; finally, in all cases, a cell block was obtained for immunocytochemical evaluation and, in one case, for FISH to detect ALK1-gene translocation. Results The median age of patients was 48 years and the mean time between the implant placement and the occurrence of peri-implant breast seroma was 18 months. Microscopic examination showed breast implant-associated anaplastic large cell lymphoma in one case, aspecific inflammatory reaction in six cases and silicon-associated reaction in one case. Conclusions Peri-implant breast seroma may be caused by several pathological conditions with different clinical behaviour. A proper cytological approach to peri-implant breast seroma allows a correct differential diagnosis between inflammatory conditions and breast implant-associated anaplastic large cell lymphoma and an appropriate management of the patient.

The association of HCV with Non-Hodgkin Lymphoma (NHL) has been demonstrated all over the world. The new interferon-free, direct antiviral agents (DAA), showed high efficacy and safety, and preliminary data seem to confirm their activity on low-grade NHL. The question arises as whether or not -and how- to treat the HCV positive patients suffering from diffuse large B cell lymphomas(DLBCL). Aim of this observational study was to evaluate whether the DAAs antiviral treatment of DLBCL/HCV-infected patients in concomitance with chemotherapy is a safe and effective option.

Mantle cell lymphoma (MCL) accounts for approximately 3–6% of all Non-Hodgkin Lymphomas (NHL). Patients’ median age at diagnosis is 68 years [1] with male predominance and median survival of 4–5 ye...